LALITA RAMNARAINE: Open Payments
NPI 1205121977 · GAINESVILLE, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$600 in 26 payments from 8 companies in 2025. Trend: 2023 $446 · 2024 $493 · 2025 $600
Food & beverage: $600
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 8 | $139 |
| Alkermes, Inc. | 5 | $120 |
| Teva Pharmaceuticals USA, Inc. | 4 | $104 |
| E.R. Squibb & Sons, L.L.C. | 3 | $74 |
| Axsome Therapeutics, Inc. | 2 | $54 |
| Neurocrine BioSciences, Inc. | 2 | $51 |
| Janssen Pharmaceuticals, Inc | 1 | $42 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $17 |
Products named: UZEDY, ARISTADA, COBENFY, ABILIFY ASIMTUFII, ABILIFY MAINTENA, Auvelity, INGREZZA, INVEGA SUSTENNA.
Industry payments across FL — which companies pay providers there.
